138 related articles for article (PubMed ID: 35848595)
1. Cell metabolomics study on synergistic anti-hepatocellular carcinoma effect of Aidi injection combined with doxorubicin.
Wang Y; Zhu X; Wang K; Cai Y; Liu C; Pan J; Sun J; Liu T; Huang Y; Li Y; Lu Y
Biomed Chromatogr; 2022 Oct; 36(10):e5451. PubMed ID: 35848595
[TBL] [Abstract][Full Text] [Related]
2. [Cell metabolomics study of ginkgo flavone aglycone combined with doxorubicin against liver cancer in synergy].
Lu Y; Wang YL; Song ZJ; Zhu XQ; Liu CH; Chen JY; Li YJ; He Y
Zhongguo Zhong Yao Za Zhi; 2022 Sep; 47(18):5040-5051. PubMed ID: 36164914
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic herb-drug interactions between Aidi injection and doxorubicin in rats with diethylnitrosamine-induced hepatocellular carcinoma.
Lu Y; Pan J; Zhu X; Zhang S; Liu C; Sun J; Li Y; Chen S; Huang J; Cao C; Wang Y; Li Y; Liu T
BMC Pharmacol Toxicol; 2021 Sep; 22(1):48. PubMed ID: 34488896
[TBL] [Abstract][Full Text] [Related]
4. Aidi injection enhances the anti-tumor impact of doxorubicin in H22 tumor-containing mice.
Lu Y; Zhang S; Zhu X; Wang K; He Y; Liu C; Sun J; Pan J; Zheng L; Liu W; Li Y; Huang Y; Liu T
J Ethnopharmacol; 2023 Mar; 303():115968. PubMed ID: 36473617
[TBL] [Abstract][Full Text] [Related]
5. The anti-hepatocellular carcinoma effect of Aidi injection was related to the synergistic action of cantharidin, formononetin, and isofraxidin through BIRC5, FEN1, and EGFR.
Lu S; Huang J; Zhang J; Wu C; Huang Z; Tao X; You L; Stalin A; Chen M; Li J; Tan Y; Wu Z; Geng L; Li Z; Fan Q; Liu P; Lin Y; Zhao C; Wu J
J Ethnopharmacol; 2024 Jan; 319(Pt 2):117209. PubMed ID: 37757991
[TBL] [Abstract][Full Text] [Related]
6. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
[TBL] [Abstract][Full Text] [Related]
7. Aidi injection reduces doxorubicin-induced cardiotoxicity by inhibiting carbonyl reductase 1 expression.
Lu Y; Liu W; Lv T; Wang Y; Liu T; Chen Y; Jin Y; Huang J; Zheng L; Huang Y; He Y; Li Y
Pharm Biol; 2022 Dec; 60(1):1616-1624. PubMed ID: 35980105
[TBL] [Abstract][Full Text] [Related]
8. Use of cellular metabolomics and lipidomics to decipher the mechanism of Huachansu injection-based intervention against human hepatocellular carcinoma cells.
Wu H; Cheng H; Luo S; Peng C; Zhou A; Chen Z; Wu H; Li Q
J Pharm Biomed Anal; 2022 Apr; 212():114654. PubMed ID: 35158184
[TBL] [Abstract][Full Text] [Related]
9. Aidi injection altered the activity of CYP2D4, CYP1A2, CYP2C19, CYP3A2, CYP2E1 and CYP2C11 in normal and diethylnitrosamine-induced hepatocellular carcinoma in rats.
Lu Y; Wang Y; He Y; Pan J; Jin Y; Zheng L; Huang Y; Li Y; Liu W
J Ethnopharmacol; 2022 Mar; 286():114930. PubMed ID: 34952190
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a rapid, selective, and sensitive LC-MS/MS method for simultaneous determination of D- and L-amino acids in human serum: application to the study of hepatocellular carcinoma.
Han M; Xie M; Han J; Yuan D; Yang T; Xie Y
Anal Bioanal Chem; 2018 Apr; 410(10):2517-2531. PubMed ID: 29492623
[TBL] [Abstract][Full Text] [Related]
11. A metabolomics approach reveals metabolic disturbance of human cholangiocarcinoma cells after parthenolide treatment.
He Y; Yu Q; Ma X; Lv D; Wang H; Qiu W; Chen XF; Jiao Y; Liu Y
J Ethnopharmacol; 2024 Jun; 328():118075. PubMed ID: 38513779
[TBL] [Abstract][Full Text] [Related]
12. Non-targeted metabolomics study for discovery of hepatocellular carcinoma serum diagnostic biomarker.
Wang S; He T; Wang H
J Pharm Biomed Anal; 2024 Feb; 239():115869. PubMed ID: 38064771
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of localized ultrasound-targeted microbubble destruction with doxorubicin liposomes in H22 mouse hepatocellular carcinoma model.
Zhu F; Jiang Y; Luo F; Li P
J Drug Target; 2015 May; 23(4):323-34. PubMed ID: 25609362
[TBL] [Abstract][Full Text] [Related]
14. The aspartate metabolism pathway is differentiable in human hepatocellular carcinoma: transcriptomics and (13) C-isotope based metabolomics.
Darpolor MM; Basu SS; Worth A; Nelson DS; Clarke-Katzenberg RH; Glickson JD; Kaplan DE; Blair IA
NMR Biomed; 2014 Apr; 27(4):381-9. PubMed ID: 24497316
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the reverse effect of Danhong injection on doxorubicin-induced cardiotoxicity in H9c2 cells: Insight by LC-MS based non-targeted metabolomic analysis.
Yi X; Zhu J; Zhang J; Gao Y; Chen Z; Lu S; Cai Z; Hong Y; Wu Y
J Pharm Biomed Anal; 2018 Apr; 152():264-270. PubMed ID: 29438868
[TBL] [Abstract][Full Text] [Related]
16. Uncovering the Mechanisms of Active Components from Toad Venom against Hepatocellular Carcinoma Using Untargeted Metabolomics.
Liang P; Ma Y; Yang L; Mao L; Sun Q; Sun C; Liu Z; Mazhar M; Yang S; Ren W
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431859
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Metabolomic Analysis Reveals Dynamic Metabolic Reprogramming in Hep3B Cells with Aflatoxin B1 Exposure.
Wang S; Yang X; Liu F; Wang X; Zhang X; He K; Wang H
Toxins (Basel); 2021 May; 13(6):. PubMed ID: 34072178
[TBL] [Abstract][Full Text] [Related]
18. Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells.
Saha SK; Yin Y; Kim K; Yang GM; Dayem AA; Choi HY; Cho SG
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28498322
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor effects of rhein and doxorubicin in hepatocellular carcinoma cells.
Wu L; Liu X; Cao KX; Ni ZH; Li WD; Chen ZP
J Cell Biochem; 2020 Oct; 121(10):4009-4021. PubMed ID: 30378155
[TBL] [Abstract][Full Text] [Related]
20. Combined anti-hepatocellular carcinoma therapy inhibit drug-resistance and metastasis via targeting "substance P-hepatic stellate cells-hepatocellular carcinoma" axis.
Li Z; Wang F; Li Y; Wang X; Lu Q; Wang D; Qi C; Li C; Li Z; Lian B; Tian G; Gao Z; Zhang B; Wu J
Biomaterials; 2021 Sep; 276():121003. PubMed ID: 34273686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
